---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-034481"
form_type: "8-K"
ticker: "OVID"
cik: "0001636651"
company_name: "Ovid Therapeutics Inc."
filed_at: "2024-08-02T23:59:59+00:00"
generated_at: "2026-05-31T13:28:27.602644+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Ovid Therapeutics enters consulting agreement with departing General Counsel Thomas Perone

## Summary
- Thomas Perone departed as General Counsel, CCO and Corporate Secretary effective July 11, 2024, as part of a workforce reduction.
- Consulting agreement effective July 11, 2024 through January 31, 2025 to transition duties.
- Perone eligible for monthly consulting fee totaling up to $55,000 over the consulting period.
- Outstanding equity awards will continue to vest during the consulting period.
- Consulting agreement includes post-termination non-solicitation covenants through one year after termination.

## SEC filing metadata
- accession: 0001628280-24-034481
- form_type: 8-K
- ticker: OVID
- cik: 0001636651
- company_name: Ovid Therapeutics Inc.
- filed_at: 2024-08-02T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1636651/000162828024034481/0001628280-24-034481-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1636651/000162828024034481/ovid-20240730.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-034481
- JSON: https://secwatch.observer/filing/0001628280-24-034481.json
- Plain text: https://secwatch.observer/filing/0001628280-24-034481.txt

## Key facts
- Executive change
  Thomas Perone departed as General Counsel, Chief Compliance Officer and Corporate Secretary at Ovid Therapeutics Inc..
  - Action: departed
  - Role: General Counsel, Chief Compliance Officer and Corporate Secretary
  source text: On June 27, 2024, Ovid Therapeutics Inc. (the “Company”) announced that Thomas Perone, the Company’s former General Counsel, Chief Compliance Officer and Corporate Secretary, would be departing from the Company in those roles, effective as of July 11, 2024 (the “Separation Date”) in connection with a workforce reduction.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1636651/000162828024034481/0001628280-24-034481-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.